Home > News > Elan: Good News for Nanotech Investors?
March 3rd, 2005
Elan: Good News for Nanotech Investors?
On Monday, Elan's (ELN) stock price dropped 70 percent on news that the company was pulling its highly touted and promising new treatment for multiple sclerosis, Tysabri, because two patients using the treatment had developed a rare nervous-system disorder. In the ensuing panic, the company lost billions in market capitalization and was downgraded by a few investment houses.
The drop may represent a real opportunity for investors who have a long-term perspective and understand the company's Nanocrystal technology.
Nanometrics Announces Upcoming Investor Events November 19th, 2014
Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014
Arrowhead to Present at Upcoming Conferences November 15th, 2014
Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014